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In this study the effect of repeated-fractional intradermal administration of diphtheria toxoid 
(DT) compared to a single administration in the presence or absence of adjuvants formulated in 
dissolving microneedles (dMNs) was investigated. Based on an adjuvant screening with a 
hollow microneedle (hMN) system, poly(I:C) and gibbsite, a nanoparticulate aluminum salt, 
were selected for further studies: they were co-encapsulated with DT in dMNs with either a full 
or fractional DT-adjuvant dose. Sharp dMNs were prepared regardless the composition and 
were capable to penetrate the skin, dissolve within 20 minutes and deposit the intended antigen-
adjuvant dose, which remained in the skin for at least 5 h.Dermal immunization with hMN in 
repeated-fractional dosing (RFrD) resulted in a higher immune response than a single-full dose 
(SFD) administration. Vaccination by dMNs led overall to higher responses than hMN but did 
not show an enhanced response after RFrD compared to a SFD administration. Co-
encapsulation of the adjuvant in dMNs did not increase the immune response further. 
Immunization by dMNs without adjuvant gave a comparable response to subcutaneously 
injected DT-AlPO4 in a 15 times higher dose of DT, as well as subcutaneous injected DT-
poly(I:C) in a similar DT dose. Summarizing, adjuvant-free dMNs showed to be a promising 
delivery tool for vaccination performed in SFD administration.
Keywords
Dissolving microneedles – diphtheria toxoid – intradermal immunization – microneedles – 
aluminum-based adjuvants – repeated-fractional vaccine delivery
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1. Introduction
Vaccination has led to the control of devastating diseases such as smallpox, poliomyelitis, 
measles and hepatitis (Du et al. 2018; Jiang, Wang, and Sun 2017; Peek, Middaugh, and 
Berkland 2008). Most vaccines are injected intramuscularly or subcutaneously. However, 
classical injection can cause pain, distress, needle-stick injuries and requires trained personnel 
(Leone et al. 2017). To overcome problems related to the hypodermic needles, less invasive 
technologies have been developed such as microneedles (Larraneta et al. 2016; Leone et al. 
2017). Microneedles are structures up to 1 mm in length capable to penetrate the stratum 
corneum, the major skin barrier, in a pain-free way (Leone et al. 2017; van der Maaden, Jiskoot, 
and Bouwstra 2012), thereby delivering the antigen into the skin, a very immune competent 
organ populated with many antigen presenting cells. This may lead to antigen dose-sparing 
(Leone et al. 2017; Li et al. 2011) compared to the conventional routes of administration. 
Dissolving microneedles (dMNs) are a microneedle type that dissolve in the skin upon insertion 
thereby releasing the encapsulated vaccine (Leone et al. 2017). Their dissolution in the skin 
allows to avoid sharp needle waste left behind after use and thus infections due to the needle 
re-use or needle-stick injuries are not possible (Kim, Park, and Prausnitz 2012). Furthermore, 
for vaccine in the solid state it may be possible to circumvent the need for a cold-chain to keep 
the antigen stable during storage and shipping (Gill and Prausnitz 2007).
Vaccines consist of attenuated organisms, inactivated pathogens and toxins or subunit antigens. 
While attenuated vaccines may revert to the virulent form, inactivated and subunit vaccines are 
safer but generally less immunogenic (Peek, Middaugh, and Berkland 2008; Reed, Orr, and Fox 
2013). Thus, to potentiate the immune response using safer vaccines, together with the optimal 
administration route, adjuvants can be used, aiming for increased immunogenicity or antigen 
dose-sparing (Leone et al. 2017; Reed, Orr, and Fox 2013; Kumru et al. 2014).
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However, adjuvants can have drawbacks such as adverse effects and they may affect vaccine 
stability (Kumru et al. 2014). A previous study revealed that repeated administration of 
fractional doses of inactivated polio vaccine by means of a hollow microneedle (hMN) can lead 
to superior IgG responses without the use of adjuvants (Schipper et al. 2016a).
In this study, we examined whether the immunogenicity of diphtheria toxoid (DT) can be 
influenced by repeated dermal administration in comparison with a single dose without or with 
the addition of adjuvants. In a previous study the effect of repeated antigen dosing was assessed 
by using hMN (Schipper et al. 2016c). In the present research, it was investigated whether 
repeated dosing by using dMNs and hMN had a similar effect on the immune response. To 
select the optimal adjuvant, the vaccination was performed by using a hMN intradermally in 
mice. This allowed to avoid time consuming dMN fabrication for all adjuvants and to screen a 
quite wide adjuvant set and to perform a relatively fast selection of them to encapsulate in the 
dMNs. Based on these studies, two adjuvants were selected for a follow-up study in which 
intradermal administration of DT and the adjuvant was performed in a single-full dose or in 
repeated-fractional dosing using either a hMN or dMNs.
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2. Materials and methods
2.1 Materials
Hyaluronan (sodium hyaluronate, HA, average Mw was 150 kDa) was purchased from Lifecore 
Biomedical (Chaska, MN, USA). Diphtheria toxoid (DT) (12.25 mg/mL in Phosphate buffered 
saline (PBS) pH 7.4) and diphtheria toxin (0.001 Lf/ml) were kindly provided by Intravacc 
(Bilthoven, The Netherlands). CpG ODN 1826 was purchased from Oligo Factory (Holliston, 
MA). Aluminum phosphate (AlPO4) was purchased from Brenntag (Ballerup, Denmark). Fetal 
bovine serum (FBS) and cholera toxin (vibrio cholera) were obtained from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Glucose solution, L-Glutamine (200 mM), penicillin-
streptomycin (10000 U/ml), and sodium bicarbonate were obtained from (Thermo-Fisher 
Scientific, Waltham, MA). Polyinosinic-polycytidylic acid (poly(I:C)) (low molecular weight) 
was purchased from Invivogen (Toulouse, France). Sterile phosphate buffered saline (PBS, 
163.9 mM Na+, 140.3 mM Cl−, 8.7 mM HPO42-, 1.8 mM H2PO4−, pH 7.4) was ordered from 
Braun (Oss, The Netherlands). 10 mM phosphate buffer (PB, 7.7 mM Na2HPO4, 2.3 mM 
NaH2PO4, pH 7.4) was prepared in the laboratory. All the chemicals used were of analytical 
grade and distilled water (18 MΩ/cm, Millipore Co.) was used for the preparation of all 
solutions.
2.2 Synthesis of boehmite and gibbsite
Nanoparticulate aluminum salts boehmite and gibbsite were synthesized as described 
previously (Buining et al. 1991; Wierenga, Lenstra, and Philipse 1998). Aluminium-iso-
propoxide (80 mM) and aluminum-sec-butoxide (80 mM) were mixed in HCl (90 mM) and 
stirred for 10 days. The solution was hydrothermally treated at 150°C (boehmite) or 85°C 
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(gibbsite) for 36h. The suspensions were dialyzed against water, autoclaved and stored at room 
temperature.
2.3 Preparation of formulations for hollow microneedle injections
In order to select the most promising adjuvants, various DT-adjuvant formulations were tested 
(Table 1) using a hMN injection system. DT was mixed in a concentration of 36 µg/ml with i) 
CpG ODN (36 µg/ml) or poly(I:C) (36 µg/ml) or cholera toxin (100 µg/ml) in PBS (pH 7.4), 
ii) the aluminum-based nanoparticles (alumNPs) gibbsite or boehmite (36 µg/ml Al3+ or 360 
µg/ml Al3+) in a sucrose (250 mM) containing histidine buffer (50 mM, pH 7.5). For the positive 
control, DT in a concentration of 500 µg/ml was mixed with AlPO4 in a concentration of 15 
mg/ml (DT-AlPO4) in PBS (pH 7.4). AlumNPs and DT-AlPO4 were incubated under 
continuous stirring at room temperature for 3 h to allow the DT adsorption on alumNPs or 
AlPO4.
2.4 DT adsorption on alumNPs and AlPO4
To determine the adsorption of free DT to alumNPs or AlPO4, after the adsorption procedure 
the samples were centrifuged for 60 minutes at 35,000 × g at 4 °C in an Avanti J-20 XP 
centrifuge (Beckman Coulter). The DT in the supernatant was quantified by measuring the 
intrinsic fluorescence intensity of DT (λex 280 nm/ λem 320 nm). The adsorption efficiency of 
DT was calculated according to the following equation:
                            (Eqn. 1)Adsorption efficieny % = (1 ―
𝑀𝐷𝑇 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 
𝑀𝐷𝑇 𝑡𝑜𝑡𝑎𝑙  ) × 100 %
where MDT in supernatant represents the mass of DT in supernatant after centrifugation, and MDT total 
is the total mass of DT used.
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2.5 Particles size and zeta potential determination
For DT-alumNPs (DT in concentration of 36 µg/ml, alumNPs in concentrations of 36 µg/ml 
Al3+ or 360 µg/ml Al3+) the particle size, polydispersity index (PDI) and zeta potential were 
determined by dynamic light scattering (DLS) and laser doppler velocimetry (Nano ZS® 
zetasizer, Malvern Instruments, Worcestershire, U.K.). To resemble the conditions for hMN 
injection and dMN arrays fabrication, samples were respectively prepared in 50 mM histidine 
(pH 7.5) or in 10 mM PB (pH 7.4).
2.6 Labeling of diphtheria, hyaluronan and alumNPs
2.6.1 Labeling for confocal microscopy
DT was labelled with Alexa Fluor 647® dye (AF647) (Life Technologies, Eugene, OR, USA) 
(λex 651 nm, λem 672 nm) (DT-AF647) according to the manufacturer's instructions. 
Hyaluronan was labelled with fluoresceinamine (FAM) (Sigma-Aldrich, St. Louis, MO, USA) 
(isomer I, λex 496 nm, λem 520 nm) (HA-FAM) following the method described by de Belder 
and Wik (de Belder and Wik 1975). Gibbsite was labelled with lumogallion (Gib-LMG) (TCI 
Europe N.V., Antwerp, Belgium) (λex 493 nm, λem 600 nm) following the method described 
by Mile et al (Mile et al. 2015).
2.6.2 Labeling for infrared detection 
DT deposition in ex vivo-mouse and -human skin was quantified by using DT labelled with 
IRDye 800CW (LI-COR, Lincoln, Nebraska USA) (λex 774 nm, λem 789 nm). DT labelling 
was performed according to the manufacturer's instructions.
2.7 Fabrication of dissolving microneedle arrays
dMN arrays (4x4 needles) were prepared as previously described (Leone 2018; Leone et al. 
2018). Briefly, 10% (w/v) HA was dissolved in PB (10 mM, pH 7.4) and stored overnight. The 
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next day, 0.3% (w/v) DT for the full dose dMNs or 0.1% (w/v) DT for the fractional dose dMNs 
was added to the HA solution. For adjuvanted dMNs, the adjuvant in a weight ratio 1:1 with 
DT was added.
A polydimethylsiloxane mold (PDMS, Sylgard 184, Dow Corning, Midland, MI, USA) 
consisting of single-array wells was made using a master template presenting solid silicon MN 
arrays (Leone 2018). The PDMS mold was used to pour the HA-DT solution in each well. After 
several vacuum cycles and centrifugation steps, the dMN arrays were dried at 37°C overnight. 
The next day, an antigen-free backplate was produced by pouring a mixture of 
vinylpolysiloxane base and catalyst (1:1 ratio) (Elite Double 32a Normal, Zhermack Group, 
Badia Polesine, Italy). Subsequently a two-component glue solution (Bison International B.V., 
Goes, The Netherlands) was poured onto each array and left curing. Finally, the arrays were 
removed from the PDMS mold, cut into individual arrays and stored at room temperature in a 
desiccator until use.
To perform confocal imaging, in preparing the dMN arrays 100% of the DT and gibbsite 
amount and 4.5% of the hyaluronan amount were replaced with their labelled counterparts (DT-
AF647, Gib-LMG and HA-FAM respectively). To perform near-infrared imaging of DT in the 
skin, 36% of the full dose of DT and 100% of the fractional dose of DT was labelled (DT-
IR800).
2.8 Human skin
Human abdomen skin was obtained from a local hospital within 24 hours after cosmetic 
surgery. After removal of the fat excess with a scalpel, the skin was placed in the -80°C freezer 
until use. Before use, the skin was thawed in a petri dish containing a wet tissue at 37°C for 1 
h and stretched with pins on parafilm-covered styrofoam. The skin was cleaned with distilled 
water and 70% ethanol before the start of the experiment.
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Fresh ex vivo human skin was used within 24 hours after cosmetic surgery. After manual 
removal of the fat excess, the skin was cleaned with Milli-Q and 70% ethanol and stretched 
with pins on parafilm-covered Styrofoam to be used.
2.9 Penetration of microneedles in ex vivo human skin
dMN arrays (n=3) were applied onto the skin by impact velocity, as described elsewhere (Leone 
et al. 2018), by using an impact insertion applicator with a constant velocity of 0.40 m/s (Leiden 
University - applicator with uPRAX controller version 0.3) and kept in the skin during 18 sec. 
Penetration efficiency (PE) was determined by trypan blue treatment of pierced skin, as 
previously described (van der Maaden, Sekerdag, et al. 2014). After removal of the stratum 
corneum by stripping the blue spots were visualized using a light microscope. The penetration 
efficiency per array was calculated as follows (Equation 2), in which 16 is the number of 
microneedles per array:
              (Eqn. 2)Penetration efficiency =
Number of blue spots
16  × 100
2.10 Dissolution of microneedles in ex vivo human skin
dMNs arrays (n=3) were applied on the skin as previously described (section 2.9) and were kept 
by the applicator for 20 min in the skin. The microneedle length before and after dissolution 
was determined with a light microscope (Axioskop and Stemi 2000-C, Carl Zeiss Microscopy 
GmbH, Göttingen, Germany) equipped with a digital camera (Axiocam ICc 5, Carl Zeiss). The 
images were analysed by ZEN 2012 blue edition software (Carl Zeiss Microscopy GmbH). The 
dissolved MN volumes were calculated as reported previously (Leone 2018).
2.11 Quantification of diphtheria delivered in ex vivo mouse and human skin
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Full dose dMN arrays (n=3 per skin type) and fractional dose dMN arrays (n=3 per skin type) 
were inserted into mouse or human skin ex vivo and the dMNs remained in the skin for 20 min. 
After dMN array removal, the near-infrared fluorescence of the delivered DT-IR800 was 
measured in a Perkin-Elmer IVIS Lumina Series III in vivo imaging system (Waltham, MA, 
USA), by using a ICG bkg excitation filter and an ICG emission filter and acquisition time 4 s, 
F-stop 2, binning 4 and field of view of 12.5 cm. Perkin-Elmer Living Image software version 
4.3.1.0 was used for image acquisition and analysis. Fluorescence data were processed using 
region of interest (ROI) analysis with background subtraction consisting of a control region of 
the skin.
A calibration curve was generated in mouse and human skin by intradermal microinjections of 
DT-IR800 of 62.5 - 1000 ng with an in house fabricated hMN injection system with uPRAX 
controller version 0.3 (Leiden University) as reported elsewhere (Schipper et al. 2016a; 
Schipper et al. 2016b; van der Maaden, Trietsch, et al. 2014).
2.12 Confocal laser scanning microscopy
Confocal laser scanning microscopy (CLSM) was performed with a Nikon TE-2000-e inverted 
microscope equipped with a C1 confocal unit. Nikon Plan Apo 10 × and 4 × objectives (with a 
numerical aperture of 0.20 and 0.45 and working distance of 15.7 and 4 respectively) were used 
respectively for microneedle and skin visualization. Nikon NIS Elements version 4.20.00 64-
bit software was used for acquisition and analysis of scans.
For dMN visualization, fluoresceinamine (FAM) and lumogallion (LMG) were excited at 488 
nm and Alexa Fluor 647 at 633 nm. The xy resolution was 1.55 μm/pixel.
For antigen and nanoparticle localization in the skin, fluorescently labelled dMNs were inserted 
into ex vivo fresh human skin for 20 minutes. After removal of the remaining dMN array, time-
lapse microscopy using CLSM as described above was performed with the skin in order to 
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visualize hyaluronan, gibbsite or DT respectively. Each 30 min, sequentially xy scans (xy 
resolution of 6.21 μm/pixel) were taken with a spatial resolution of 10 µm in z-direction (z-axis 
of 0.7 mm) over a time period of 5 h.
2.13 Immunization studies
Immunization studies were performed using female BALB/c mice (H2d), 8-11 weeks old 
(Charles River, Maastricht, The Netherlands). The studies were approved by the ethical 
committee on animal experiments of Leiden University (License number 14241). The mice 
were randomly assigned to groups of 8.
Immunizations were given at day 1 (prime immunization), day 22 (boost immunization) and 
day 43 (2nd boost immunization). Before each intradermal immunization, the mice were shaved 
on the left flank (approximately 4 cm2). A blood sample was collected, serum was isolated and 
stored at -80°C. Prior to vaccination, mice were anesthetized by intraperitoneal injection of 150 
mg/kg ketamine and 10 mg/kg xylazine. At day 63, all mice were sacrificed and serum was 
collected.
2.13.1 Part I: adjuvant screening
The effect of adjuvants on the immunogenicity of dermally injected DT was assessed using 
hMN injection (Table 1). The inner diameter of the hMN was approximately of 150 μm and the 
length of the microneedle tip of approximately 120 μm. Injected volume was 10 µl at a 
controlled depth of 120 µm by using a specifically designed hMN injection system with uPRAX 
controller version 0.3 (Leiden University) (van der Maaden, Trietsch, et al. 2014). Negative and 
positive controls included respectively intradermal injection of PBS by hMN and 100 µl 
subcutaneous injection of 5 µg DT and 150 µg AlPO4 with a conventional 26G needle.
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Table 1. Immunization study parameters for adjuvant screening. The dose of DT and adjuvant 
is provided together with the immunization route. Two ratios of DT and alumNPs were used.
*) DT: diphtheria toxoid; CT: cholera toxin; PI: poly(I:C); Gib: gibbsite; Boe: boehmite; AlPO4: aluminum 
phosphate, **) Al3+ concentration.
2.13.2 Part II: single-full dose vs repeated-fractional doses
The effects of DT administration, with and without adjuvant, in repeated-fractional doses 
(RFrD) were investigated and compared to a single-full dose (SFD) injection (100% dose). The 
RFrD consisted of administration, in 3 consecutive days, of 1/3rd of the SFD of DT(-adjuvant) 
(3 x 33% doses). Intradermal vaccination in mice was performed using hMN (10 µl at a depth 
of 120 µm) and dMNs. Details of the formulations are reported in Table 2. PBS and DT- AlPO4 
groups were used as negative and positive control, respectively. An additional positive control 
of subcutaneous injection of 100 µl of 0.36 µg DT and 0.36 µg poly(I:C) was included.
Table 2. Immunization study parameters for administration kinetics investigation. The 
administration is in SFD (100%) or in 3 RFrD (3 x 33%).
*) the DT and adjuvant dose are equal except for the subcutaneous injection with AlPO4, in 
which 5 µg of DT and 150 µg AlPO4 has been added in the formulation; **) application of an 
empty dMN array or injection of PBS on 2 consecutive days and DT administration in SFD on 
day 3. Abbreviations are DT: diphtheria toxoid; Gib: gibbsite; PI: poly(I:C); AlPO4: aluminum 
phosphate; E: empty dMN array.
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2.14 Determination of DT-specific serum IgG titers and diphtheria toxin-neutralizing 
antibody titers
DT-specific total IgG, IgG1 and IgG2a titers in serum were determined by ELISA as described 
previously (Schipper et al. 2017). Plates were coated with 140 ng DT per well and incubated 
overnight at 4 °C. After blocking with BSA (Sigma-Aldrich, Zwijndrecht, The Netherlands), 
sera samples were added in a three-fold serial dilution and the plates were incubated at 37 °C 
for 2 h. Detection of antibodies was performed with horseradish peroxidase-conjugated goat-
anti-mouse IgG, IgG1 or IgG2a (Southern Biotech, Birmingham, AL) (1:5000 dilution) using 
1-stepTM ultra 3,3',5,5'-tetramethylbenzidine (TMB) (Thermo-Fisher Scientific, Waltham, 
MA) as substrate. The reaction was stopped with 2M sulfuric acid (JT Baker, Deventer, The 
Netherlands). Absorbance was measured at 450 nm. Antibody titers were expressed as the log10 
value of the serum dilution at the mid-point of the S-shaped absorbance-dilution curve. 
Toxin neutralizing capacity of antisera was measured in a Vero cell assay (Ding et al. 
2009). After complement inactivation by heating at 56 °C for 45 min, appropriate two-fold 
serial dilutions of serum samples were prepared in M199 medium (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) (supplemented with 5% FBS (Sigma-Aldrich, Zwijndrecht, The 
Netherlands), 1 g/l glucose, 1.6 mM L-glutamine, 1.7 g/l sodium bicarbonate and 100 U/ml 
penicillin-streptomycin) and were applied to 96-well plates. Subsequently, 50 μl/well 0.001 
Lf/ml diphtheria toxin diluted in complete culture medium was added and the plates were 
incubated at 37°C and 5% CO2 for 2 h for toxin neutralization. Subsequently, 50 μl/well 
suspension of Vero cells were added (12,500 cells/well) and incubated at 37 °C in 5% CO2 for 
6 days. The number of wells containing viable Vero cells was determined by microscopy. The 
neutralizing antibody titers were expressed as the log2 value of the highest serum dilution that 
was still capable of protecting the Vero cells from the challenge of diphtheria toxin.
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2.15 Statistical analysis
Data from antibody titers and neutralizing antibody titers were analyzed by one way ANOVA 
with Bonferroni post-test by using GraphPad Prism software (version 5.02). A p < 0.05 was 
considered to be significant. 
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3 Results
3.1 Size and zeta potential of DT-alumNPs and adsorption efficiency of DT to alumNPs 
and to AlPO4
DT-Gibbsite and DT-Boehmite were characterized in terms of particle size, polydispersity 
index (PDI) and zeta potential. DT-alumNPs were in the µm range, i.e. outside the measuring 
range of the DLS equipment, regardless the buffer composition (data not shown).
The effect of the type of particle on the zeta potential was examined. In histidine buffer, 
boehmite resulted in a positive surface charge, while gibbsite showed a negative zeta potential 
at the same concentration. When increasing the particle concentration the zeta potential became 
less negative for the boehmite and became positive for the gibbsite. The effect of the addition 
of DT on the zeta potential was also examined. It was observed that i) addition of DT to the 
alumNPs formulation resulted in a lower zeta potential than alumNPs only and ii) increasing 
the DT:alumNPs ratio from 1:1 to 1:10 by increasing the alumNP concentration resulted in a 
higher zeta potential, indicating a relative lower level of negatively charged DT on their surface 
compared with the slightly positively charged alumNPs (Table 3). No significant changes in 
zeta potential were observed within the first 24 h of storage (Table 3). The alumNPs in PB 
showed a more negative zeta potential than in histidine buffer.
The adsorption efficiency of DT on the alumNPs and AlPO4 at 3 h after mixing was measured 
(Table 3). In solutions with DT : alumNPs 1:10 ratio more than 80% DT was adsorbed to the 
alumNPs. For a DT : alumNPs 1:1 ratio the DT adsorption on the alumNPs was less than 40%. 
This was also observed for the AlPO4 particles. This indicated that at equal weight ratios the 
alumNP surface became saturated with DT.
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Table 3. Zeta potential of DT-alumNPs and percentages of DT adsorption on alumNPs and 
AlPO4 (n = 3). Data are average ± SEM.
*) 36 µg/ml Al3+, **) 360 µg/ml Al3+
3.2 Immunization study for adjuvant screening
In an immunization study using a hMN several adjuvants were screened on their efficiency to 
potentiate the immune response of DT. The selected adjuvants were CpG ODN, Poly(I:C), 
cholera toxin, gibbsite and boehmite (the latter two in DT : alumNPs ratios of 1:1 and 1:10).
After the prime, the groups DT-Gib 1:1 and DT-Boe 1:10 induced higher IgG titers than the 
DT group (Fig 1 A). The DT-Boe 1:10 group showed even a comparable response to the positive 
control DT-AlPO4 (Fig 1 A).
At day 42, DT-specific total IgG titers increased further for all formulations (Fig 1 B). However, 
no significant adjuvant effect was observed in comparison with the DT control group (Fig 1 B). 
The DT-CT group had a comparable IgG response to the positive control DT-AlPO4.
At day 63 (Fig 1 C), the response of all the groups was very close to the response of positive 
control DT-AlPO4, despite a 15 fold lower dose (Fig 1 C). However, the addition of different 
adjuvants did not enhance further the response evoked by DT after three vaccinations (Fig 1 C).
Figure 1. DT-specific total IgG titers on day 21 (A), 42 (B) and 63 (C). After each vaccination, 
the AlPO4 was significantly different from each other group except the no significant (ns) group 
reported. After 63 days, the titers in the DT-Gib 1:10 group was significantly lower (s.dif.) 
compared to the titers in all the other groups. Bars represent mean ± SEM, n = 8. *p < 0.05, **p 
< 0.01, ***p < 0.001 and ****p < 0.0001. DT dose was 0.36 µg except DT-AlPO4 sc: 5 µg. 
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hMN: hollow microneedle; DT: diphtheria toxoid; PI: poly(I:C); CT: cholera toxin; Gib: 
gibbsite; Boe: boehmite; AlPO4: aluminum phosphate.
Besides the IgG total response, the IgG1 and IgG2a responses were also measured. IgG1 and 
IgG2a ratios were not dependent on adjuvant type (Supplementary material, Figure S1) 
(p>0.05). This indicates that the Th2/Th1 balance was not influenced by the adjuvants.
The functionality of the antibody response was investigated by determining toxin neutralizing 
antibody titers in serum on day 63. The positive control DT-ALPO4 showed higher levels of 
toxin-neutralizing antibodies than all other groups (p<0.05) (Fig 2). Overall, the addition of an 
adjuvant to DT did not improve the functional response. Similarly to the IgG total titers, DT-
Gibbsite 1:10 was less immunogenic as compared to plain DT.
Based on neutralizing antibody results and the primary response, poly(I:C) and gibbsite (the 
formulation in 1:1 ratio with DT) were selected as adjuvants for the studies using dMNs.
Figure 2. DT-neutralizing antibody titers. Results are shown for serum collected on day 63. 
The titers in the DT-Gib 1:10 group and the DT-AlPO4 group were, respectively, significantly 
lower or higher (s.dif.) from the titers in all the other groups. Bars represent mean ± SEM, n = 
8. hMN: hollow microneedle; DT: diphtheria toxoid; PI: poly(I:C); CT: cholera toxin; Gib: 
gibbsite; Boe: boehmite; AlPO4: aluminum phosphate.
3.3 Dissolving microneedle: characterization and interaction with the skin
dMN arrays were prepared with DT in absence or presence of the selected adjuvant. Very sharp 
dMNs containing either DT, DT-PI or DT-Gib could be prepared (Fig 3) in a reproducible 
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manner. The DT content (full dose or fractional dose) did not affect the shape either (Fig 3 and 
data not shown).
Fig 3. Brightfield microscope images (5x) of microneedles with DT, DT-PI and DT-Gib full 
dose content before application on the skin (0 min) and after 20 minutes dissolution into ex vivo 
human skin. Scale bar 100 µm.
Hyaluronan, DT and gibbsite were uniformly distributed within the dMN as investigated with 
confocal 3D imaging using fluorescently labelled components (Figure 4).
Fig 4. CLSM 3D images of the distribution of fluorescently labelled HA (A) and DT (B) in the 
hyaluronan-based dMNs containing DT; Fluorescently labelled HA (C), DT (D) and Gib (E) in 
hyaluronan-based dMNs containing DT adsorbed gibbsite nanoparticles. Both dMNs (A-B and 
C-E) contained a full dose of DT or DT-Gib. Scale bar 100 µm.
dMN arrays prepared from full dose of either DT, DT-PI or DT-Gib were applied on ex vivo 
human skin. After withdrawal and application of trypan blue, the number of blue spots were 
determined and the penetration efficiency and the standard deviation were calculated being 
respectively 95.8 ± 7.2%, 89.6 ± 9.5% and 100.0 ± 0.0%, respectively (n = 3).
As shown in figure 3, dMNs with DT or DT-PI incorporated dissolved completely in the skin 
within 20 min (100 ± 0% dissolved MN volume, mean ± sd), the dMNs with DT-Gib 
incorporated resulted in some dMN leftover (approximately 91 ± 1% dissolved volume, mean 
± sd).
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After 20 min microneedle dissolution in fresh human skin and withdrawal of the remaining 
dMN array, the hyaluronan, DT and gibbsite were visualized in the skin by CLSM during 5 
hours each 30 minutes as function of depth parallel to the skin surface (Fig 5, only 0, 3 and 5 h 
time points are shown). All components were deposited and co-localized in the epidermis and 
top layers of the dermis. Furthermore, the delivered antigen without or with gibbsite remained 
at the site of administration for at least 5 h, whereas HA is mostly diffused away after 3 h or 
less.
Fig 5. CLSM 3D images of HA (green), DT (red) and Gib (yellow) localization into ex vivo 
human (fresh) skin after dMN arrays application for 20 min. Deposited HA (A, C, E) and DT 
(B, D, F) fluorescently labelled (HA-FAM and DT-AF647) into the skin after dissolution of 
hyaluronan dMNs loaded with DT; deposited DT (G, I, K) and gibbsite (H, J, L) fluorescently 
labelled (DT-AF647 and Gib-LMG) into the skin after dissolution of hyaluronan dMNs loaded 
with DT and gibbsite. Images related to time 0 h (A, B, G, H), 3 h (C, D, I, J) and 5 h (E, F, K, 
L) are shown. Time 0 h refers to the beginning of the detection, starting after the dMN 
dissolution of 20 min and removal of the dMN array. The location of the skin surface is the xy 
area on top of the z-axis representing the depth of imaging (0.7 mm).
Finally, the amount of DT delivered into the skin after dMN array application using infrared 
labelled DT was determined. After 20 min of application in the skin, the dMNs containing a 
full or 1/3 dose of DT delivered respectively 0.32 ± 0.02 µg and 0.13 ± 0.04 µg of DT in ex 
vivo human skin and 0.35 ± 0.03 µg and 0.10 ± 0.01 µg of DT in ex vivo mouse skin (mean ± 
sd, n = 3).
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3.4 dMN arrays and hMNs: single-full dose vs. repeated-fractional dose
The aim of this study was to compare RFrD with SFD administration of DT with or without 
adjuvant using dMN arrays and a hMN keeping the total dose of DT and antigen approximately 
the same.
Following prime vaccination by a hMN, IgG titers after DT RFrD were higher than DT SFD 
(Fig. 6 A). To determine whether MN piercing itself has an effect on the immune response, a 
hMN group (PBS/PBS/DT SFD) consisting of two consecutive days of PBS injection and a 
third day of SFD DT injection was included. As the IgG titers were higher than that of the SFD 
injection, microneedle piercing as such seems to enhance the immune response.
Prime administration of DT by dMNs gave higher IgG responses than hMN injection (Fig 6 A). 
DT RFrD by dMNs did not significantly increase the IgG levels compared to DT SFD by dMNs, 
although there is a trend of a higher response and after RFrD there is less variation in the 
response. Additionally, the application of empty dMN arrays in the first two days and the SFD 
administration of the DT on the third day (E/E/DT SFD) showed a comparable IgG response as 
RFrD. The encapsulation of an adjuvant (poly(I:C) or gibbsite) together with DT in the dMNs, 
did not increase the DT-specific total IgG response when delivered as SFD or RFrD compared 
to the absence of an adjuvant. Finally, the administration of DT by dMNs gave a higher response 
than the control of DT-poly(I:C) injected subcutaneously and a response comparable to the 
positive control, DT-ALPO4 sc, with a 15 times higher DT dose. Conversely, the hMN groups 
showed comparable response to the control of DT-PI sc and a significantly lower response than 
the positive control DT-ALPO4 sc.
After the first boost, DT-specific total IgG titers increased (Fig. 6 B) but the differences between 
the groups were similar as after the prime with a few changes. DT RFrD by dMNs was 
comparable to DT RFrD using hMN but still higher than PBS/PBS/DT SFD hMN group. 
Furthermore, the positive controls DT-PI and DT-AlPO4 subcutaneously injected were 
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comparable to all hMN and dMNs groups except to DT SFD hMN and DT SFD hMN and 
PBS/PBS/DT SFD hMN groups, respectively, which showed a significant lower response.
After the second boost (Fig 6 C) the titers of most groups further increased, although slightly. 
Apparently a plateau in the immune response was reached. After this second boost, for the first 
time the DT RFrD dMNs group developed a higher response than E/E/DT SFD dMNs.
Fig. 6. DT-specific total IgG antibody titers measured in BALB/c mice on day 21 (A), day 42 
(B) and day 63 (C). Bars represent mean ± SEM, n = 8. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. SFD: single-full dose; RFrD: repeated-fractional dose; dMNs: dissolving 
microneedles; hMN: hollow microneedle; DT: diphtheria toxoid; PI: poly(I:C); Gib: gibbsite; 
E: empty dMNs; AlPO4: aluminum phosphate.
The IgG1/IgG2a ratios are depicted in Figure S2 in Supplementary material. DT vaccination by 
dMNs and addition of gibbsite or poly(I:C) as adjuvant modestly changed the IgG1/IgG2a ratio, 
shifting the balance slightly to Th1.
High levels of toxin-neutralizing antibodies were induced after vaccination by means of dMNs, 
regardless the dosing modality or the presence of an adjuvant, and by DT RFrD by hMN (Fig 
7). No adjuvant effect was observed after addition of PI in dMNs (DT SFD dMNs gave a similar 
response compared to DT-PI SFD dMNs and DT-PI SFD sc), but DT-PI RFrD dMNs resulted 
higher in response compared to DT-PI SFD dMNs and DT-PI SFD sc. In this case, the dosing 
modality made a difference in protection against the toxin, resulting a RFrD of DT-PI in a much 
higher toxin neutralization.
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Figure 7. DT-neutralizing antibody titers. Results are shown for serum collected on day 63. 
Bars represent mean ± SEM, n = 8. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. SFD: 
single-full dose; RFrD: repeated-fractional dose; dMNs: dissolving microneedles; hMN: hollow 





The aim of this study was to obtain insight in whether dermal vaccination by RFrD of DT 
enhances the specific IgG response compared to that after SFD antigen dermal administration. 
The present study corroborated existing data (Schipper et al. 2016a; Johansen et al. 2008) by 
showing a superior response by RFrD compared to SFD of antigen after vaccination by hMN. 
In the present study less consecutive days of administration were used as in the previous studies: 
33% in each consecutive day during 3 days vs 4, 7 and 8 days in the previous studies. 
Furthermore, low responders seemed to benefit more from the RFrD regime and it was 
demonstrated that consecutive skin piercing by hMN (PBS/PBS/DT SFD) could enhance the 
immune response compared to a DT SFD only by hMN. Piercing of the skin may cause some 
cell death or other local damage resulting in the release of damage-associated molecular 
patterns (DAMPs) and subsequent attraction of antigen presenting cells to the immunization 
area (Depelsenaire et al. 2014). However, application of empty dMN arrays (E/E/DT SFD), 
inducing an even higher number of piercings in the skin compared to a hMN (16 dMNs per 
array vs 1 hMN) and applied by a 20 minutes pressure on the skin potentially leading to skin 
inflammation (Depelsenaire et al. 2014; Meliga et al. 2013). This did not enhance the response 
further compared to a SFD antigen administration by dMNs. This may be explained by a 
maximal level of immunity reached after prime for the E/E/DT SFD group due to the skin 
piercing by the first empty array application inducing release of DAMPs and then an immune 
response with no additional further effect after application of the other empty and then DT 
loaded dMN arrays. 
dMNs vs a hMN
24
Vaccination by means of dMNs led to significantly higher response than by hMN, as already 
reported in our previous study (Leone 2018), showing a faster increase in DT-specific IgG 
responses already after the first immunization. This can be related to several factors. First, the 
use of different MN types: a hMN injects the vaccine at a specific intradermal depth point (120 
µm) while the longer dMNs (300 µm) release the antigen at various skin depths simultaneously 
possibly reaching a higher number of immune cells and involving different immune cell 
populations (Matsuo et al. 2014), although in literature no difference in the immune response 
is reported when comparing different injection depths (Schipper et al. 2016b). Second, the 
number of needles piercing the skin (16 dMNs vs 1 hMN) and the pressure applied on the skin 
(20 minutes for the dMN array application and no pressure for the hMN) potentially causing 
inflammation and thus more release of DAMPs in a larger region, facilitating attraction of 
antigen presenting cells. Third, the presence of low molecular weight species of HA. Although 
high MW HA is considered immunologically inert, low molecular weight HA fragments, 
potentially present in the dMNs or generated in vivo, can elicit various proinflammatory 
responses leading to innate immune activation (Termeer et al. 2002; Termeer et al. 2000), 
although this is not observed in recent studies in our group (Leone et al, manuscript submitted) 
and in literature (Oh et al. 2010). Fourth, the prolonged exposure of the antigen during dMN 
dissolution to relevant immune cells may enhance the response (Gatto et al. 2007). Fifth, the 
presence of low responding and no-responding mice after prime vaccination in SFD by hMN: 
in a previous study (Schipper et al. 2017) and in the adjuvants screening of the present study, 
the titers after DT vaccination by hMN resulted in an overall higher response being closer to 
the positive control DT-AlPO4 than in the SFD vs RFrD immunization study.
Adjuvants vs repeated-fractional dosing by dMNs
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Antigen dose sparing can be achieved with the use of adjuvants (Ding et al. 2009; Reed, Orr, 
and Fox 2013). Besides adjuvants (CpG, PI and CT) commonly used for experimental dermal 
vaccination (Ding et al. 2009; Du et al. 2018; Leone et al. 2017), aluminum-based NPs 
(alumNPs), so far tested only for subcutaneous or intramuscular administration (Crepeaux et al. 
2015; Reed, Orr, and Fox 2013; Gupta 1998), were included for intradermal vaccination.
The selection, in the first immunization study by hMN, of the optimal adjuvants for DT 
vaccination by dMNs led to the choice of poly(I:C) and gibbsite. Poly(I:C) gave a more robust 
response after primary immunization, similar to CT, than other adjuvants and it has a better 
feasibility for human vaccination than CT. The selection of gibbsite (in ratio 1:1 with DT) was 
based on the following considerations: i) its higher response among the DT adjuvanted with 
alumNPs and ii) dermal injection of gibbsite, as of boehmite too, did not induce any palpable 
persistent intradermal injection-site nodules in mice, as previously observed after intradermal 
injection of classical aluminum preparations (Vogelbruch et al. 2000).
The addition of adjuvants for intradermal vaccination by both hMN and dMNs did not enhance 
the IgG total levels further compared to unadjuvanted antigen indicating that the response 
reached already a plateau and any extra did not lead to a higher response. However, vaccination 
by dMNs, in the presence of poly(I:C) or gibbsite, shifted the Th2/Th1 balance to Th1. This 
was not observed using hMNs. This change in response may be related to the depot created in 
the skin after dMN dissolution leading to a sustained release of antigen and adjuvant (Gatto et 
al. 2007).
In our study, similarly potent DT-specific IgG responses were observed upon intradermal 
vaccination by dMNs of SFD, RFrD and adjuvanted DT. This demonstrates that by using dMNs 
the immune response can be enhanced and the use of an adjuvant or prolonged antigen delivery 
by fractional dosing can be avoided, at least for potent antigens. An adjuvant-free vaccine would 
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then avoid side-effects and potential stability problems related to the presence of the adjuvant 
(Kumru et al. 2014; Mbow et al. 2010).
However, results from neutralizing antibody assay indicated a higher protection against 
diphtheria toxin for adjuvanted-DT RFrD dMNs compared to unadjuvanted DT in dMNs, hMN 
groups and even conventional injection of DT-PI. This may be related to a prolonged exposure 
of the antigen during and after dMN dissolution to relevant immune cells involved in the 
humoral protection as mentioned above.
Overall these observations lead to the conclusion that the combination of RFrD and adjuvant in 
dMNs, but not their separated use, can be very efficient in respect to the antibody response and 
the neutralization of the diphtheria toxin effect.
Finally, Joice et al (Joyce et al. 2019) reported how extended-delivery vaccination by means of 
dMNs enables a single vaccination to generate immune responses equivalent to a two-dose 
vaccination regimen for vaccines as IPV, tetanus toxoid and influenza but the same extended-
delivery vaccination does not enhance immune response to the live-attenuated measles vaccine. 
This demonstrates that RFrD of the antigen can lead to a superior immune response than SFD 
depending on the antigen type.
dMNs vs conventional subcutaneous injections
This study focused on minimally-invasive delivery for DT immunization by dMNs and it has 
been shown that vaccination by dMNs loading unadjuvanted DT led to comparable responses 
already after prime immunization as compared to invasive subcutaneous injections of DT-
AlPO4 with almost 15 and 415 times higher DT and adjuvant doses respectively. These results 
corroborated existing data in literature where a comparable or even higher response was 
obtained after vaccination by dMNs than conventional subcutaneous injection (Bachy et al. 
2013; Edens et al. 2015; Matsuo et al. 2014; Pattani et al. 2011; Zhu et al. 2016) and similar 
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response was shown after vaccination with hMN in comparison with the above mentioned 
positive control (Du et al. 2018; Schipper et al. 2017). Higher IgG responses after prime and 
comparable responses after the two boost immunizations demonstrate the efficiency of a dermal 
vaccination by dMNs compared to subcutaneous injection of adjuvanted-DT (DT-PI sc).
Characterization of the alumNPs
Fabrication of dMN arrays and dMN interaction with the skin, regardless the formulation, was 
successful as previously demonstrated (Leone 2018). However, dissolution of DT-Gib was not 
complete after 20 minutes. This may be related to the particle aggregation observed in the 
alumNPs characterization studies. Aggregation is likely due to the pH, as the alumNPs are 
stable at pH<6 and aggregate above this value (H. Vrieling et al, manuscript in preparation).
Boehmite and gibbsite were characterized in the transmission electron microscope for their 
shape and size resulting in nm range (Buining, Philipse, and Lekkerkerker 1994; Verhoeff, 
Brand, and Lekkerkerker 2011). In the present study their size resulted in the µm range using 
dynamic light scattering (data not shown). This suggests that particle aggregation occurred. 
Besides the presence of DT and the concentration of alumNPs, the buffer composition also had 
a role on the zeta potential: PB lowered the zeta potential more than the histidine buffer. A 
possible explanation can be found in the phosphate groups from PB exchanging with hydroxyl 




In conclusion, when using hMN a delivery of the antigen over multiple days can enhance the 
immune response more than a SFD delivery. The SFD vaccination by dMNs can enhance a 
much higher response than hMN, however fractional delivery administration by using dMNs 
does not lead to a superior response. Moreover, dMNs demonstrate no further increase in 
response by co-encapsulation of the adjuvant and a comparable or even higher response than, 
respectively, the current benchmarks: AlPO4 adsorbed DT and DT-PI administered 
subcutaneously. These findings demonstrate the potential of dMNs as vaccine delivery device 
addressing to a SFD administration of an adjuvant-free vaccine to have a fast and high 
functional response.
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Appendix A: Supplementary material
Figure S1. DT-specific IgG1 and IgG2a ratio titers on day 63. Bars represent mean ± SEM, n 
= 8. No significant difference among the groups was found (p > 0.05). hMN: hollow 
microneedle; DT: diphtheria toxoid; PI: poly(I:C); CT: cholera toxin; Gib: gibbsite; Boe: 
boehmite; AlPO4: aluminum phosphate.
Figure S2. DT-specific IgG1 and IgG2a ratio titers measured in BALB/c mice on day 63. Bars 
represent mean ± SEM, n = 8. *p < 0.05, **p < 0.01, ***p < 0.001. SFD: single-full dose; 
RFrD: repeated-fractional dose; dMNs: dissolving microneedles; hMN: hollow microneedle; 










Table 1. Immunization study parameters for adjuvant screening. The dose of DT and adjuvant 
is provided together with the immunization route. Two ratios of DT and alumNPs were used.
Immunization route Intradermal by hollow microneedle Subcutaneous
Group name*) DT DT-CT DT-PI DT-CpG ODN DT-Gib DT-Boe PB
S
DT- AlPO4 sc
1:1 1:10 1:1 1:10
DT dose (µg) 0.36 - 5
Adjuvant dose (µg) - 1 0.36 0.36**) 3.6 **) 0.36 **) 3.6 **) - 150
*) DT: diphtheria toxoid; CT: cholera toxin; PI: poly(I:C); Gib: gibbsite; Boe: boehmite; AlPO4: aluminum 
phosphate, **) Al3+ concentration.
36
Table 2. Immunization study parameters for administration kinetics investigation. The 
administration is in SFD (100%) or in 3 RFrD (3 x 33%).



















Subcutaneous injection (conventional 26G needle)
DT-PI SFD 0.36
DT-AlPO4 SFD 5
*) the DT and adjuvant dose are equal except for the subcutaneous injection with AlPO4, in 
which 5 µg of DT and 150 µg AlPO4 has been added in the formulation; **) application of an 
empty dMN array or injection of PBS on 2 consecutive days and DT administration in SFD on 
day 3. Abbreviations are DT: diphtheria toxoid; Gib: gibbsite; PI: poly(I:C); AlPO4: aluminum 
phosphate; E: empty dMN array.
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Table 3. Zeta potential of DT-alumNPs and percentages of DT adsorption on alumNPs and 
AlPO4 (n = 3). Data are average ± SEM.
Time (h)
0 3 24
Formulation Buffer Zeta Potential (mV) Adsorption 
efficiency (%)
Gibbsite*) -24.7 ± 0.4 - - -
DT*-Gibbsite*) 1:1
PB
-32.6 ± 0.5 -32.8 ± 0.3 -32.1 ± 0.3 27.1 ± 0.5
Gibbsite*) -0.9  ± 0.3 - - -
DT*-Gibbsite*) 1:1 -27.1 ± 0.1 -27.0 ± 0.2 -26.7 ± 0.2 11.4 ± 1.0
Gibbsite**) 17.6 ± 0.3 - - -
DT*-Gibbsite**) 1:10 -22.8 ± 0.3 -22.5 ± 0.2 -19.0 ± 0.6 81.3 ± 0.1
Boehmite*) 3.4 ± 0.4 - - -
DT*-Boehmite*) 1:1 -23.8 ± 0.2 -23.2 ± 0.2 -25.7 ± 0.1 25.5 ± 0.4
Boehmite**) 13.9 ± 0.5 - - -
DT*-Boehmite**) 1:10
Histidine
-15.4 ± 0.6 -8.5 ± 0.2 -4.7 ± 0.5 83.2 ± 0.1
DT-AlPO4 1:30 PBS - - - 38.7 ± 0.3
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